are relenza sales biting into tami sales???, page-18

Hopefully we will get more than 2 bidding for LANI.

We don't want to be subservient to one bidder where they make the rules. We want to have better conditions compared to Relenza such as regular payments instead of once yearly, higher royalty and also good marketing for the product.

I would imagine the worst thing would be to have a vaccine maker selling it and for it to be a part of a suite of products in the antiviral market. We want an aggresive company who knows how to manufacture and then market the product for maximum sales and therefore this should mean maximum gain to us.